Japan TMT Analyst

Pelham Smithers

Market Intel on Asian Tech with a Japan focus

Pelham Smithers Associates

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

Research is provided by the following:
Pelham Smithers: Macro, consumer electronics, telecoms & pharma
Joel Scheiman: Electronics materials / components
Julie Boote: Autos
Will Nestuk: Capital goods, machinery & transportation equipment parts
Thao Nguyen: eCommerce, internet content, marketing & advertising

Equity Bottom-Up

<p style="text-align: left;"><a href="https://www.smartkarma.com/entities/4489" target="_blank" data-smartkarma-citation="entities:4489:1">Chugai Pharmaceutical (4519 JP)</a> announced on August 24<sup>th</sup> that the US FDA has accepted its Biologics License Application (BLA) for emicizumab (emi) on Priority Review for adults, adolescents and children with haemophilia A with Factor VIII inhibitors, resulting in a PDUFA date of 23<sup>rd</sup> February 2018. The announcement was made with one hour of trading left and, if anything, the shares weakened on the news, which underscores that there was little by way of surprise here. The 79% effectiveness and…</p>

Chugai Pharmaceutical (4519 JP) announced on August 24th that the US FDA has accepted its Biologics License Application (BLA) for emicizumab (emi) on Priority Review for adults, adolescents and children with haemophilia A with Factor VIII inhibitors, resulting in a PDUFA date of 23rd February 2018. The announcement was made with one hour of trading left and, if anything, the shares weakened on the news, which underscores that there was little by way of surprise here. The 79% effectiveness and…

Chugai Pharmaceutical (4519 JP): Emicizumab Gets PDUFA Data

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

MSCI Emerging Markets Index / Technical Analysis

<p>Bullish technicals continue to support our call to overweight EM. We highlight actionable themes, as well as pullback opportunities in Europe, European luxury/apparel, UK homebuilders, EM chemicals, Japanese chemicals, and Japanese tech stocks.</p>

Bullish technicals continue to support our call to overweight EM. We highlight actionable themes, as well as pullback opportunities in Europe, European luxury/apparel, UK homebuilders, EM chemicals, Japanese chemicals, and Japanese tech stocks.

Int'l Compass: Overweight EM; Actionable Themes in Europe and Japan

<p>News that gilteritinib has received orphan drug status for acute myeloid leukaemia (AML) would be rather more exciting for <strong><a href="https://www.smartkarma.com/entities/6091" target="_blank" data-smartkarma-citation="entities:6091:1">Astellas (4503 JP)</a></strong> but for the fact that AML is the new favourite treatment area for the FDA. In December 2016, Escend received a similar designation for ES-3000, while Boehringer Ingelheim’s volasertib and <strong><a href="https://www.smartkarma.com/entities/16469" target="_blank" data-smartkarma-citation="entities:16469:1">Prescient Therapeutics' (PTX AU)</a></strong> PTX-200 both gained orphan status this May. AML is a ¥100bil/yr market, so it is on the large side for orphan status.</p><p>AML has proven…</p>

News that gilteritinib has received orphan drug status for acute myeloid leukaemia (AML) would be rather more exciting for Astellas (4503 JP) but for the fact that AML is the new favourite treatment area for the FDA. In December 2016, Escend received a similar designation for ES-3000, while Boehringer Ingelheim’s volasertib and Prescient Therapeutics' (PTX AU) PTX-200 both gained orphan status this May. AML is a ¥100bil/yr market, so it is on the large side for orphan status.AML has proven…

Update on Astellas (4503) As It Gets Orphan Drug Status for Gilteritinib

<p>Earlier this year, <strong><a href="https://www.smartkarma.com/entities/11747" target="_blank" data-smartkarma-citation="entities:11747:1">Takeda Pharmaceutical Co Ltd (4502 JP)</a></strong> spent US$4bil on <a href="https://www.smartkarma.com/entities/13299" target="_blank" data-smartkarma-citation="entities:13299:1">Ariad Pharmaceuticals Inc (ARIA US)</a>, thereby acquiring a company with a questionable reputation on pricing (Iclusig, a blood cancer drug, is the most expensive drug of its type, listed at US$200,000, a price that was raised because the FDA narrowed its indication because of adverse side-effects) and one pipeline asset, brigantinib. The latter, an ALK+ inhibitor, anti-cancer drug has just been approved by the FDA for use…</p>

Earlier this year, Takeda Pharmaceutical Co Ltd (4502 JP) spent US$4bil on Ariad Pharmaceuticals Inc (ARIA US), thereby acquiring a company with a questionable reputation on pricing (Iclusig, a blood cancer drug, is the most expensive drug of its type, listed at US$200,000, a price that was raised because the FDA narrowed its indication because of adverse side-effects) and one pipeline asset, brigantinib. The latter, an ALK+ inhibitor, anti-cancer drug has just been approved by the FDA for use…

Korea / Special Situations, Clepsydra Capital

Sanghyun Park

Korea / Special Situations

Thematic (Sector/Industry)

<div><div class="content-highlight"><h2>Japan</h2></div></div><h2>Strong pick-up truck sales in US</h2><p><a href="https://www.smartkarma.com/profiles/940" target="_blank" data-smartkarma-citation="accounts:940">Nick Tanner</a> suggested paying attention to the continued recovery of US pick-up truck sales for <a href="https://www.smartkarma.com/entities/15064" target="_blank" data-smartkarma-citation="entities:15064:1">Toyo Tire &amp; Rubber Co Ltd (5105 JP)</a>, nearly 60% of whose operating profit is coming from North America. However, Nick cautiously pointed out that we might want to closely watch Toyo's profitability this year, which is expected to be slightly lower than that of last year. <a href="https://www.smartkarma.com/profiles/713" target="_blank" data-smartkarma-citation="accounts:713">Mio Kato, CFA</a> also put out a piece on the strong pick-up sales in US. He argued that the ongoing…</p>

JapanStrong pick-up truck sales in USNick Tanner suggested paying attention to the continued recovery of US pick-up truck sales for Toyo Tire &amp; Rubber Co Ltd (5105 JP), nearly 60% of whose operating profit is coming from North America. However, Nick cautiously pointed out that we might want to closely watch Toyo's profitability this year, which is expected to be slightly lower than that of last year. Mio Kato, CFA also put out a piece on the strong pick-up sales in US. He argued that the ongoing…

The Week That Was in NorthAsia@Smartkarma: Trucks, Pachinko, and Life Insurance

Japan

Chugai Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals products. The Company develops drugs in the fields of cancer, infectious diseases, bone, blood, and circulatory systems. Chugai Pharmaceutical also conducts research studies on drugs with private and public medical research institutions globally.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Chugai Pharmaceutical (4519 JT)

Chugai Pharmaceutical (4519 JP): Emicizumab Gets PDUFA Data

Chugai Pharmaceutical (4519 JP) announced on August 24th that the US FDA has accepted its Biologics License Application (BLA) for emicizumab (emi)...

Pelham Smithers Associates

Int'l Compass: Overweight EM; Actionable Themes in Europe and Japan

Bullish technicals continue to support our call to overweight EM. We highlight actionable themes, as well as pullback opportunities in Europe,...

Vermilion Research

Update on Astellas (4503) As It Gets Orphan Drug Status for Gilteritinib

News that gilteritinib has received orphan drug status for acute myeloid leukaemia (AML) would be rather more exciting for Astellas (4503 JP) but...

Pelham Smithers Associates

Takeda - Brigantinib Gets FDA Approval

Earlier this year, Takeda Pharmaceutical Co Ltd (4502 JP) spent US$4bil on Ariad Pharmaceuticals Inc (ARIA US), thereby acquiring a company with a...

Pelham Smithers Associates

The Week That Was in NorthAsia@Smartkarma: Trucks, Pachinko, and Life Insurance

JapanStrong pick-up truck sales in USNick Tanner suggested paying attention to the continued recovery of US pick-up truck sales for Toyo Tire &...

Sanghyun Park

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)